CAJ | 학술논문

为探讨卵巢癌隐含的耐药机制及其对化疗的影响，用RT-PCR方法对7例正常卵巢组织及32例卵巢癌进行了多药耐药基因(mdr1)检测，结果表明：正常卵巢组织中，mdr1基因均无表达，32例卵巢癌中，mdr1表达阳性率为28.1%，mdr1基因表达与病理类型有关(P＜0.05)，而且mdr1表达阳性者耐药发生率(55.6%)显著高于阴性者(8.6%，P＜0.01)。结果提示：卵巢癌中隐含有由mdr1介导的多药耐药机制，mdr1的表达与卵巢癌的化疗耐药有一定的关系。
위탐토란소암은함적내약궤제급기대화료적영향，용RT-PCR방법대7례정상란소조직급32례란소암진행료다약내약기인(mdr1)검측，결과표명：정상란소조직중，mdr1기인균무표체，32례란소암중，mdr1표체양성솔위28.1%，mdr1기인표체여병리류형유관(P＜0.05)，이차mdr1표체양성자내약발생솔(55.6%)현저고우음성자(8.6%，P＜0.01)。결과제시：란소암중은함유유mdr1개도적다약내약궤제，mdr1적표체여란소암적화료내약유일정적관계。
To inverstigate the potential drug resistance mechanism and the possible contribution of the multidrug resistance phenotype to chemoresistance in ovarian cancer, the mdr1 gene expression was analyzed by using the RT-PCR technique in 7 cases of normal ovary and 32 cases of ovarian carcinoma. Results showed that mdr1 gene was expressed in 9 cases (28.1%) with ovarian carcinoma,but negative expression in normal ovary tissues was found. The expression of mdr1 gene was associated with histologic type (P＜0.05). The patients with mdr1+ had much higher resistance rate (55.6%) than that of mdr1- cases (8.6%) to chemotherapy. The results suggested that the expression of mdr1 gene might contribute to drug resistance in ovarian carcinomas.